Ioana Kloos

1.3k total citations
33 papers, 459 citations indexed

About

Ioana Kloos is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Ioana Kloos has authored 33 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Molecular Biology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Ioana Kloos's work include CAR-T cell therapy research (13 papers), Lymphoma Diagnosis and Treatment (12 papers) and Histone Deacetylase Inhibitors Research (11 papers). Ioana Kloos is often cited by papers focused on CAR-T cell therapy research (13 papers), Lymphoma Diagnosis and Treatment (12 papers) and Histone Deacetylase Inhibitors Research (11 papers). Ioana Kloos collaborates with scholars based in France, United States and Netherlands. Ioana Kloos's co-authors include Laurent Bastit, Karine Briot, M. Tubiana-Hulin, Christian Roux, Franck Morschhauser, Bertrand Coiffier, Vincent Ribrag, Stéphane Depil, Suzette Delaloge and Ying Luan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Ioana Kloos

33 papers receiving 449 citations

Peers

Countries citing papers authored by Ioana Kloos

Since Specialization

Citations

This map shows the geographic impact of Ioana Kloos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ioana Kloos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ioana Kloos more than expected).

Fields of papers citing papers by Ioana Kloos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ioana Kloos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ioana Kloos. The network helps show where Ioana Kloos may publish in the future.

Co-authorship network of co-authors of Ioana Kloos

This figure shows the co-authorship network connecting the top 25 collaborators of Ioana Kloos. A scholar is included among the top collaborators of Ioana Kloos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ioana Kloos. Ioana Kloos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study 2025 ·Blood ·Julio C. Chávez, Michael Dickinson, Javier Muñoz, Matthew L. Ulrickson, Catherine Thiéblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, (unknown), Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wulff, (unknown), Joshua D. Winters, Ioana Kloos, Hairong Xu, Sattva S. Neelapu	3
2	Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor 2024 ·Advances in Therapy ·Gilles Salles, (unknown), (unknown), Fábio R. Kerbauy, James J. Wu, Sally W. Wade, Ana Paiva Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia Thornton Snider, (unknown), Keith Chan, (unknown), Bijal Shah	1
3	Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis 2024 ·Leukemia & lymphoma ·James J. Wu, Sally W. Wade, Taha Itani, (unknown), Ioana Kloos, Weimin Peng, Steve Kanters, Michael J. Zoratti, Martin Dreyling, Bijal Shah, Michael Wang	1
4	S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT 2023 ·HemaSphere ·Nausheen Ahmed, (unknown), Mehdi Hamadani, Natalie S. Grover, Mazyar Shadman, Frederick L. Locke, James N. Gerson, Matthew J. Frank, Lihua E. Budde, Michael Wang, Zhen‐Huan Hu, Ana Paiva Nunes, David Dalton, Ioana Kloos, Daniel Y. Lee, (unknown), Marcelo C. Pasquini, Alex F. Herrera	1
5	MCL-373 Unmet Need in Relapsed/Refractory (RR) Mantle Cell Lymphoma (MCL) Post-Bruton Tyrosine Kinase Inhibitor (BTKi): Systematic Literature Review and Meta-Analysis 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Martin Dreyling, Bijal Shah, James J. Wu, Taha Itani, Michael J. Zoratti, Steve Kanters, Sally W. Wade, Weimin Peng, (unknown), Ioana Kloos, Michael Wang	1
6	Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England 2022 ·Journal of Medical Economics ·(unknown), Gilles Salles, Michael Wang, James J. Wu, Sally W. Wade, (unknown), Craig Bennison, (unknown), Weimin Peng, Ioana Kloos, (unknown), Georg Heß	6
7	Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients (Pts) with Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial 2021 ·Transplantation and Cellular Therapy ·Michael Wang, John M. Rossi, Javier Muñoz, André Goy, Frederick L. Locke, Patrick M. Reagan, Caron A. Jacobson, Brian T. Hill, Houston Holmes, Samantha Jaglowski, Weimin Peng, Lianqing Zheng, Xiang Fang, Allen Xue, Ioana Kloos, Adrian Bot	2
8	Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma 2019 ·Haematologica ·(unknown), (unknown), (unknown), Susana Hernández-García, Luís A. Corchete, Laura San‐Segundo, (unknown), (unknown), Marie Schoumacher, Sébastien Banquet, Laurence Kraus‐Berthier, Ioana Kloos, (unknown), Ensar Halilovic, Heiko Maacke, Norma C. Gutiérrez, María‐Victoria Mateos, Teresa Paíno, Mercedes Garayoa, Enrique M. Ocio	42
9	Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity In AML 2018 ·Experimental Hematology ·Jessica M. Salmon, Giovanna Pomilio, Donia M. Moujalled, Sarah MacRaild, Charis E. Teh, Sewa Rijal, Adam Ivey, (unknown), Paul G. Ekert, Marie Schoumacher, Laurence Kraus‐Berthier, Ioana Kloos, Daniel H.D. Gray, Andrew H. Wei	2
10	Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study 2017 ·Haematologica ·Vincent Ribrag, Won Seog Kim, Réda Bouabdallah, Soon Thye Lim, Bertrand Coiffier, Árpád Illés, Bernard Lemieux, Martin J.S. Dyer, Fritz Offner, (unknown), Ioana Kloos, Ying Luan, Remus Vezan, Thorsten Graef, Franck Morschhauser	71
11	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia 2016 ·Leukemia & lymphoma ·Norbert Vey, Thomas Prébet, Claire Thalamas, Aude Charbonnier, Jérôme Rey, Ioana Kloos, Emily Liu, Ying Luan, Remus Vezan, Thorsten Graef, Christian Récher	15
12	A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors 2016 ·Oncotarget ·Éric Deutsch, Elizabeth Cohen‐Jonathan Moyal, Vanesa Gregorc, Paolo Andrea Zucali, (unknown), Jean‐Charles Soria, Ioana Kloos, Jeff Hsu, Ying Luan, Emily Liu, Remus Vezan, Thorsten Graef, Sofía Rivera	10
13	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia 2015 ·Investigational New Drugs ·Franck Morschhauser, Louis Terriou, Bertrand Coiffier, Emmanuel Bachy, Andréa Varga, Ioana Kloos, Hélène Lelièvre, (unknown), Stéphane Depil, Vincent Ribrag	32
14	Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients 2014 ·Investigational New Drugs ·(unknown), Sylvain Fouliard, Mélanie White‐Koning, Ioana Kloos, Étienne Chatelut, Marylore Chenel	12
15	Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I 2013 ·European Journal of Cancer ·Sylvain Fouliard, (unknown), (unknown), (unknown), Sriram Balasubramanian, David Loury, Yohann Loriot, Antoine Hollebecque, Ioana Kloos, Jean‐Charles Soria, Marylore Chenel, Stéphane Depil	23
16	Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor 2013 ·Pharmaceutical Research ·(unknown), Sylvain Fouliard, (unknown), (unknown), Ioana Kloos, Stéphane Depil, Étienne Chatelut, Marylore Chenel	9
17	Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients 2012 ·Blood ·Franck Morschhauser, Louis Terriou, Bertrand Coiffier, Gilles Salles, Ioana Kloos, Nicolas Tavernier, Stéphane Depil, Vincent Ribrag	2
18	Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study 2009 ·Breast Cancer Research and Treatment ·Karine Briot, M. Tubiana-Hulin, Laurent Bastit, Ioana Kloos, Christian Roux	91
19	Effects of switching aromatase inhibitors on arthralgia: the ATOLL study. 2009 ·Cancer Research ·Karine Briot, Laurent Bastit, (unknown), D. Spaëth, (unknown), Ioana Kloos, I. Bourdeix, (unknown)	6
20	Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature 2002 ·International Journal of Gynecological Cancer ·Ioana Kloos, Suzette Delaloge, Patricia Pautier, Mario Di Palma, A Goupil, Pierre Duvillard, (unknown), C. Lhommé	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact